Is 002022.SZ overvalued or undervalued?

002022.SZ currently has a P/E ratio of -4.54. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Shanghai Kehua Bio-engineering Co., Ltd. stock?

Shanghai Kehua Bio-engineering Co., Ltd. trades on SHZ. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 002022.SZ?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 002022.SZ protect my money against local inflation?

Many investors in Latin America buy international stocks like 002022.SZ to protect their purchasing power. Because 002022.SZ is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 002022.SZ shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 002022.SZ a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 002022.SZ diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks002022.SZ

Shanghai Kehua Bio-engineering Co., Ltd.

¥6.20+¥0.15+2.48%

SHZ / CNY

Market cap

¥3.2B

P/E

-4.5

EPS (TTM)

¥-0.20

Dividend yield

—

Beta

0.25

1Y return

-2.36%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$764M2021

$1.0B2022

$342M2023

$241M2024

$235M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.28Low
Current ratio1.74
Cash ratio0.63
Net margin-41.7%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

002022.SZ-4.5
Healthcare sector median26.8
S&P 50022.0

Trades about 117% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.97
Price to book1.27
EPS (TTM)¥-0.20
Payout ratio-148%
FCF yield-3.82%

Range & risk

¥4.47¥7.54

Trading in the middle of its 52-week band

Beta0.25

Profile

What Shanghai Kehua Bio-engineering Co., Ltd. actually does

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

CEO

Li Ming

Employees

1,870

Headquarters

Shanghai, SH

Founded

2004-07-21

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 002022.SZ and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

002022.SZ has a beta of 0.25, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Shanghai Kehua Bio-engineering Co., Ltd.